Total Payments
$2,269
2024 Payments
$1,199
Companies
30
Transactions
79
Medicare Patients
9,715
Medicare Billing
$3.6M
Payment Breakdown by Category
Food & Beverage$2,269 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,269 | 79 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $278.71 | 11 | $0 (2024) |
| Celgene Corporation | $266.30 | 12 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $228.90 | 11 | $0 (2024) |
| PFIZER INC. | $176.39 | 9 | $0 (2024) |
| Medtronic, Inc. | $160.50 | 1 | $0 (2023) |
| Janssen Biotech, Inc. | $150.05 | 3 | $0 (2024) |
| GENZYME CORPORATION | $121.84 | 1 | $0 (2024) |
| Genentech USA, Inc. | $120.65 | 1 | $0 (2022) |
| Ethicon US, LLC | $120.02 | 1 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $72.74 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,199 | 49 | Lilly USA, LLC ($206.34) |
| 2023 | $619.84 | 22 | Medtronic, Inc. ($160.50) |
| 2022 | $449.56 | 8 | Genentech USA, Inc. ($120.65) |
All Payment Transactions
79 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $27.75 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $23.40 | General |
| Category: Oncology | ||||||
| 11/12/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $121.84 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $41.41 | General |
| 11/06/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $17.94 | General |
| Category: Oncology | ||||||
| 11/04/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $20.21 | General |
| 10/31/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $4.13 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $1.67 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $19.02 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $0.73 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $26.17 | General |
| Category: ONCOLOGY | ||||||
| 10/21/2024 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $25.12 | General |
| Category: Oncology | ||||||
| 09/25/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $24.89 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $21.85 | General |
| Category: ONCOLOGY | ||||||
| 09/11/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $20.29 | General |
| Category: Oncology | ||||||
| 09/04/2024 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $25.21 | General |
| Category: ONCOLOGY | ||||||
| 08/26/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $18.32 | General |
| Category: Oncology | ||||||
| 08/19/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $21.66 | General |
| Category: Iron Deficiency Anemia | ||||||
| 08/14/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $26.61 | General |
| Category: Oncology | ||||||
| 08/13/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $21.51 | General |
| 08/12/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $24.16 | General |
| Category: Oncology | ||||||
| 08/07/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $32.88 | General |
| 07/24/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $31.30 | General |
| 07/23/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | Cash or cash equivalent | $70.13 | General |
| Category: Oncology | ||||||
| 07/15/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $26.09 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 67 | 6,517 | 281,384 | $8.0M | $3.2M |
| 2022 | 46 | 2,708 | 68,294 | $1.0M | $368,305 |
| 2021 | 16 | 490 | 18,001 | $117,435 | $49,247 |
Total Patients
9,715
Total Services
367,679
Medicare Billing
$3.6M
Procedure Codes
129
All Medicare Procedures & Services
129 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 16 | 30,000 | $3.2M | $1.3M | 41.3% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 11 | 23,580 | $2.1M | $886,574 | 41.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 33 | 12,661 | $531,762 | $233,910 | 44.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 673 | 2,354 | $513,254 | $219,607 | 42.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 82 | 678 | $189,840 | $66,980 | 35.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 156 | 448 | $131,636 | $60,916 | 46.3% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 113 | 142,800 | $285,600 | $56,288 | 19.7% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 19 | 8,290 | $132,640 | $50,693 | 38.2% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 589 | 2,179 | $65,370 | $22,544 | 34.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 119 | 119 | $50,125 | $19,829 | 39.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 241 | 312 | $46,800 | $19,075 | 40.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 167 | 390 | $57,720 | $18,648 | 32.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 565 | 2,362 | $51,964 | $17,900 | 34.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 562 | 2,122 | $29,708 | $17,809 | 59.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 140 | 140 | $46,760 | $17,430 | 37.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 70 | 796 | $50,148 | $17,399 | 34.7% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 16 | 260 | $41,080 | $14,218 | 34.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 41 | 221 | $30,719 | $10,791 | 35.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 52 | 70 | $29,050 | $9,605 | 33.1% |
| 96416 | Administration of prolonged chemotherapy into vein | Office | 2023 | 18 | 83 | $23,489 | $8,045 | 34.3% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 313 | 534 | $20,826 | $7,125 | 34.2% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 22 | 150 | $18,450 | $6,311 | 34.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 32 | 67 | $14,271 | $6,242 | 43.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 77 | 505 | $25,755 | $5,483 | 21.3% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 256 | 342 | $14,706 | $5,055 | 34.4% |
About Andrew Marple, M.D., PH.D
Andrew Marple, M.D., PH.D is a Hematology & Oncology healthcare provider based in Sarasota, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/27/2015. The National Provider Identifier (NPI) number assigned to this provider is 1083093769.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Andrew Marple, M.D., PH.D has received a total of $2,269 in payments from pharmaceutical and medical device companies, with $1,199 received in 2024. These payments were reported across 79 transactions from 30 companies. The most common payment nature is "Food and Beverage" ($2,269).
As a Medicare-enrolled provider, Marple has provided services to 9,715 Medicare beneficiaries, totaling 367,679 services with total Medicare billing of $3.6M. Data is available for 3 years (2021–2023), covering 129 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Sarasota, FL
- Active Since 05/27/2015
- Last Updated 08/12/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1083093769
Products in Payments
- VERZENIO (Drug) $187.10
- SIGNIA (Device) $160.50
- REBLOZYL (Biological) $138.26
- IBRANCE (Drug) $126.95
- SARCLISA (Biological) $121.84
- TECENTRIQ (Biological) $120.65
- Certus 140 (Device) $120.02
- ERLEADA (Drug) $115.06
- PLUVICTO (Drug) $92.39
- MONJUVI (Drug) $70.39
- JAYPIRCA (Drug) $70.13
- ENHERTU (Biological) $52.27
- MONOFERRIC (Drug) $47.46
- MYRISK (Device) $46.54
- CAMCEVI (Drug) $45.42
- MEKINIST (Drug) $40.46
- KISQALI (Drug) $39.84
- TASIGNA (Drug) $33.41
- VYNDAQEL (Drug) $31.40
- OPDIVO (Biological) $26.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Sarasota
Steven Mamus, M.d, M.D
Hematology & Oncology — Payments: $31,342
Hematology & Oncology $31,342
Dr. Manjesh Lingamurthy, M.d, M.D
Hematology & Oncology — Payments: $24,000
Hematology & Oncology $24,000
Dr. Galina Vugman, Md, MD
Hematology & Oncology — Payments: $2,521
Hematology & Oncology $2,521
Rodrigo Garcia, M.d, M.D
Hematology & Oncology — Payments: $203.42
Hematology & Oncology $203.42
Dr. Raymond Markham, M.d, M.D
Hematology & Oncology — Payments: $23.93
Hematology & Oncology $23.93
Hubert Gerrry, M.d, M.D
Hematology & Oncology
Hematology & Oncology